Biosimilar Efficacy

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

Interchangeable status enables pharmacy substitution where state laws allow, signaling expanding pathways for oncology biosimilars.